Morphic Holding Inc

NASDAQ:MORF   4:00:00 PM EDT
28.62
+0.93 (+3.36%)
4:15:40 PM EDT: $28.62 0.00 (0.00%)
Products, Regulatory

Morphic Holding Announces Initiation Of Emerald-2 Phase 2B Clinical Trial Of Morf-057 In Patients With Moderate-To-Severe Ulcerative Colitis

Published: 11/22/2022 13:07 GMT
Morphic Holding Inc (MORF) - Morphic Announces Initiation of Emerald-2 Phase 2b Clinical Trial of Morf-057 in Patients With Moderate-to-severe Ulcerative Colitis.
Morphic Holding Inc - Looking Forward to Results of Emerald-1 Phase 2a Study of Morf-057 That is Expected in Q2 of 2023.
Morphic Holding Inc - Top Line Results From Emerald-2 Are Expected in First Half of 2025.